Skip to main content
Shilpa Medicare Ltd. logo

Shilpa Medicare Ltd. — Investor Relations & Filings

Ticker · SHILPAMED ISIN · INE790G01031 LEI · 3358002PKUL8S2RNJO60 BSE.NS Manufacturing
Open in API
Filings indexed 817 across all filing types
Latest filing 2026-06-03 M&A Activity
Country IN India
Listing BSE.NS SHILPAMED

About Shilpa Medicare Ltd.

https://vbshilpa.com/

Shilpa Medicare Ltd. is a research-led organization specializing in the development, manufacture, and commercialization of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. The company maintains a significant focus on the oncology segment, producing a wide range of high-potency anti-cancer drugs. Its capabilities extend to diverse therapeutic areas, including ophthalmology, dermatology, and biosimilars. Shilpa Medicare operates manufacturing facilities compliant with international regulatory standards such as the USFDA and EU-GMP. The organization emphasizes complex chemistry and advanced drug delivery systems, offering a portfolio that includes oral solids, injectables, and transdermal patches. Through its R&D infrastructure, the company provides contract research and manufacturing services to global partners, supporting the lifecycle of generic and innovative pharmaceutical products.

Recent filings

Filing Released Lang Actions
Shilpa Biocare Private Limited, a wholly owned Subsidiary of Shilpa Medicare Limited, intends to make a strategic equity partnership in Gate2Brain.
M&A Activity Classification · 78% confidence The document is a formal regulatory disclosure under SEBI Listing Obligations (Regulation 30) announcing that Shilpa’s wholly-owned subsidiary will acquire a 30.4% equity stake in Gate2Brain. It includes detailed annexure on transaction terms and consideration. This is not a fundraising or share-issuance notice, nor is it an annual or interim report. It is an acquisition announcement, fitting the M&A Activity category.
2026-06-03 English
Press Release
Regulatory Filings Classification · 75% confidence The document is a press release filed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing stock exchanges of a strategic equity partnership (30.4% stake acquisition) by the company’s wholly owned subsidiary. There is no financial statement content, no mention of annual or interim report data, nor is it a proxy, dividend, or earnings release. It is a required regulatory disclosure of an acquisition transaction rather than a full M&A takeover filing or financial report. Therefore, it falls under the generic Regulatory Filings category (RNS).
2026-06-03 English
USFDA Inspection of Shilpa Medicare Limited at Unit VI, Dabaspet, Bengaluru
Regulatory Filings Classification · 11% confidence The document is an official regulatory disclosure under SEBI (LODR) Regulation 30 notifying the stock exchanges about a USFDA Pre-Approval Inspection and the issuance of Form 483 observations. It is not a full financial report, earnings release, or AGM material, nor does it announce a capital change, management change, or other specific category. It is a general compliance/regulatory announcement, fitting the fallback category Regulatory Filings (RNS).
2026-05-30 English
General Updates
Regulatory Filings Classification · 85% confidence The document is an intimation under Regulation 30 of SEBI (LODR) Regulations, addressed to BSE and NSE, disclosing a USFDA Pre-Approval Inspection at a manufacturing unit and associated observations. This is a regulatory event disclosure rather than a financial report, earnings release, dividend notice, or proxy solicitation. It does not present financial statements or detailed management discussion; it simply informs the stock exchanges of a compliance event under listing obligations. Therefore, it falls under the general "Regulatory Filings" category (RNS).
2026-05-30 English
Annual Secretarial Compliance Report for the financial year 2025-26
Regulatory Filings Classification · 91% confidence The document is an Annual Secretarial Compliance Report prepared by a Practicing Company Secretary and submitted under SEBI LODR Regulation 24A. It is a compliance attestation/certification rather than a financial report or management discussion. The Certification Rule applies, indicating this should be classified as a general regulatory filing. Therefore, it falls under Regulatory Filings (RNS).
2026-05-28 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is explicitly titled “Transcript of the Q4FY26 Conference call” and contains the full text of Shilpa Medicare Limited’s quarterly results earnings call presentation and discussion. This matches the definition of a Call Transcript (CT).
2026-05-26 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.